Evidence map›Paper›PMID 40066297›Full record

ReviewNpj biological timing and sleep2025

Dual orexin receptor antagonists as promising therapeutics for Alzheimer's disease.

S M Ragsdale, J M Radovich, I I Coiduras, W V McCall, S C Grant, C Lee, A Wilber

Abstract readReview
In one paragraph

Review in Npj biological timing and sleep, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Observational
  5. Selective orexin receptor cross-over treatment increases resilience and expression of neuroplastic signaling genes.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026
    Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Psychiatric Risk Factors for Progression From Mild Cognitive Impairment to Alzheimer's Disease: A Systematic Review.The American journal of geriatric psychiatry. Open science, education, and practice · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

S M RagsdaleDepartment of Psychology; Program in Neuroscience; Florida State University, Tallahassee, FL USA.
J M RadovichDepartment of Chemical & Biochemical Engineering, FAMU-FSU College of Engineering, Florida State University, Tallahassee, FL USA.
I I CoidurasDepartment of Psychology; Program in Neuroscience; Florida State University, Tallahassee, FL USA.
W V McCallDepartment of Psychiatry and Health Behavior; Medical College of Georgia; Augusta University, Augusta, GA USA.
S C GrantDepartment of Chemical & Biochemical Engineering, FAMU-FSU College of Engineering, Florida State University, Tallahassee, FL USA.
C LeeDepartment of Biomedical Sciences; Program in Neuroscience; College of Medicine, Florida State University, Tallahassee, FL USA.
A WilberDepartment of Psychology; Program in Neuroscience; Florida State University, Tallahassee, FL USA.

Funding

Dysfunction of Sodium Homeostasis in MigraineR01NS072497 · NINDS · HUNTINGTON MEDICAL RESEARCH INSTITUTES · PI ARAKAKI, XIANGHONG, GRANT, SAMUEL COLLES · 2011 to 2023
$4.8M
Targeting the orexin pathway to treat sleep disorders and improve glymphatic clearance in Alzheimer’s diseaseR01AG070094 · NIA · FLORIDA STATE UNIVERSITY · PI WILBER, AARON A · 2021 to 2025
$2.4M
MR Analysis of Pre-Conditioned Human Mesenchymal Stem Cells for Stroke TherapyR01NS102395 · NINDS · FLORIDA STATE UNIVERSITY · PI GRANT, SAMUEL COLLES · 2017 to 2021
$1.7M
Molecular mechanisms underlying human circadian sleep disordersR01GM131283 · NIGMS · FLORIDA STATE UNIVERSITY · PI LEE, CHOOGON · 2019 to 2022
$1.2M
Neurobiological Basis of Reference Frame Coordination for Spatial Memory to Action TransformationsR56MH133929 · NIMH · FLORIDA STATE UNIVERSITY · PI WILBER, AARON A · 2024 to 2025
$1.0M
Parietal-hippocampal network in the triple transgenic mouse model of AlzheimersR00AG049090 · NIA · FLORIDA STATE UNIVERSITY · PI WILBER, AARON A · 2017 to 2019
$747k
A novel cell-based platform to study human circadian disordersR01GM147340 · NIGMS · FLORIDA STATE UNIVERSITY · PI LEE, CHOOGON · 2023 to 2024
$595k
Parietal-hippocampal network in the triple transgenic mouse model of AlzheimersK99AG049090 · NIA · UNIVERSITY OF CALIFORNIA-IRVINE · PI WILBER, AARON A · 2015 to 2016
$189k
NIA NIH HHS K99 AG049090NIA NIH HHS R00 AG049090NIA NIH HHS R01 AG070094NIGMS NIH HHS R01 GM131283NIGMS NIH HHS R01 GM147340NIMH NIH HHS R56 MH133929NINDS NIH HHS R01 NS072497NINDS NIH HHS R01 NS102395
6 · The paper itself

Abstract

We examine the relationship between sleep, glymphatics and Alzheimer's disease (AD), and recent work questioning glymphatic clearance during sleep. We highlight a need for understanding glymphatic and/or other mechanism of clearance during sleep, and review glymphatic flow measurement methods. Further, we explore dual orexin receptor antagonists (DORAs) potential to mitigate AD sleep disturbances and enhance clearance. Further research could elucidate a linkage between DORAs, improved sleep and reducing AD pathophysiology.

Indexed as

Biological techniquesDiseasesNeuroscience

Identifiers

PMID40066297
PMCPMC11890173

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.